CELETTI, ANGELA
 Distribuzione geografica
Continente #
NA - Nord America 221
AS - Asia 96
EU - Europa 36
Totale 353
Nazione #
US - Stati Uniti d'America 220
SG - Singapore 82
IT - Italia 19
FI - Finlandia 12
KR - Corea 9
CN - Cina 5
DE - Germania 2
GB - Regno Unito 2
MX - Messico 1
NL - Olanda 1
Totale 353
Città #
Santa Clara 203
Singapore 63
Helsinki 12
Seoul 9
Naples 4
Marigliano 3
Milan 3
Ashburn 2
Falkenstein 2
Avellino 1
Changzhou 1
Fort Worth 1
London 1
Mexico City 1
Phoenix 1
Seattle 1
Springfield 1
Totale 309
Nome #
CCDC6 (coiled-coil domain containing 6) 13
Osteopontin is overexpressed in human papillary thyroid carcinomas and enhances thyroid carcinoma cell invasiveness. 13
NSCLC Mutated Isoforms of CCDC6 Affect the Intracellular Distribution of the Wild Type Protein Promoting Cisplatinum Resistance and PARP Inhibitors Sensitivity in Lung Cancer Cells. 11
Loss of CCDC6, the first identified RET partner gene, affects pH2AX S139 levels and accelerates mitotic entry upon DNA damage. 11
HOMEOBOX-CONTAINING GENES AS MOLECULAR MARKERS IN HEMATOPOIESIS 10
Analysis of codherin/catenin complexes in transformed thyroid epithelial cells: Modulation by beta 1 integrin subunit 10
CCDC6 and USP7 expression levels suggest novel treatment options in high-grade urothelial bladder cancer 11 Medical and Health Sciences 1112 Oncology and Carcinogenesis 06 Biological Sciences 0601 Biochemistry and Cell Biology 10
Critical role of CCDC6 in the neoplastic growth of testicular germ cell tumors. 10
The between now and then of lung cancer chemotherapy and immunotherapy 9
USP7 inhibitors, downregulating CCDC6, sensitize lung neuroendocrine cancer cells to PARP-inhibitor drugs 9
The rationale for druggability of CCDC6-tyrosine kinase fusions in lung cancer 9
New combinatorial strategies to improve the PARP inhibitors efficacy in the urothelial bladder Cancer treatment 9
New therapeutic perspectives in CCDC6 deficient lung cancer cells 9
MAPK15 upregulation promotes cell proliferation and prevents DNA damage in male germ cell tumors 9
Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: The rationale for their inclusion in the clinic 9
Identification of sumoylation sites in CCDC6, the first identified RET partner gene in papillary thyroid carcinoma, uncovers a mode of regulating CCDC6 function on CREB1 transcriptional activity. 9
CCDC6: The identity of a protein known to be partner in fusion 9
CCDC6 represses CREB1 activity by recruiting histone deacetylase 1 and protein phosphatase 1 8
CAF-1 subunits levels suggest combined treatments with PARP-inhibitors and ionizing radiation in advanced HNSCC 8
Epigenetics of oral and oropharyngeal cancers (Review) 8
Thyroid hormone and androgen signals mutually interplay and enhance inflammation and tumorigenic activation of tumor microenvironment in prostate cancer 8
SELECTION OF ACTIVATING MUTATIONS OF C-FMS IN FDC-P1 CELLS 7
Analysis of CCDC6 as a novel biomarker for the clinical use of PARP1 inhibitors in malignant pleural mesothelioma 7
L'osteopontina: un nuovo marcatore biologico dei carcinomi della testa e del collo 7
Mono(ADP-ribosyl)ation Enzymes and NAD+ Metabolism: A Focus on Diseases and Therapeutic Perspectives 7
CHARACTERISTIC PATTERNS OF HOX GENE-EXPRESSION IN DIFFERENT TYPES OF HUMAN LEUKEMIA 7
The combined effect of USP7 inhibitors and PARP inhibitors in hormone-sensitive and castration-resistant prostate cancer cells. 7
Coordinate regulation ofHOX genes in human hematopoietic cells 7
FKBP51 immunohistochemical expression: A new prognostic biomarker for OSCC? 7
A xCT role in tumour-associated ferroptosis shed light on novel therapeutic options 7
Novel Markers for Diagnosis and Prognosis of Oral Intraepithelial Neoplasia 7
Epigenetic Mechanisms: Histone Acetylation, DNA Methylation, miRNA, Chromatin Modifiers 6
Low frequency of p53 mutations in human thyroid tumors: p53 and Ras mutation in two aut of fifty-six thyroid carcinomas 6
The disruption of the CCDC6 - PP4 axis induces a BRCAness like phenotype and sensitivity to PARP inhibitors in high-grade serous ovarian carcinoma 6
Autocrine stimulation by osteopontin plays a pivotal role in the expression of the mitogenic and invasive phenotype of RET/PTC-transformed thyroid cells. 6
H4(D10S170), a gene frequently rearranged with RET in papillary thyroid carcinomas: functional characterization. 6
The tumour suppressor CCDC6 is involved in ROS tolerance and neoplastic transformation by evading ferroptosis 6
Expression Signature 6
Overexpression of the cytokine osteopontin identifies aggressive laryngeal squamous cell carcinomas and enhances carcinoma cell proliferation and invasiveness. 6
H4 (D10S170), un gene frequentemente riarrangiato con RET nei carcinomi papilliferi tiroidei: caratterizzazione funzionale. 6
OPN/CD44v6 overexpression in laryngeal dysplasia and correlation with clinical outcome. 6
FBXW7 and USP7 regulate CCDC6 turnover during the cell cycle and affect cancer drugs susceptibility in NSCLC. 6
Expression of the RET receptor tyrosine kinase and GDNF-Ra in normal and leukemic human hematopoietic cells and stromal cells of the bone marrow mic 5
Nucleotide Excision Repair and head and neck cancers. 5
Reduced E-cadherin expression contributes to the loss of p27kip1-mediated mechanism of contact inhibition in thyroid anaplastic carcinomas. 5
³Involvement of H4(D10S170) protein in ATM-dependent response to DNA damage² 5
Overexpression of chromatin assembly factor-1 p60, poly(ADP-ribose) polymerase 1 and nestin predicts metastasizing behaviour of oral cancer. 5
Involvement of H4(D10S170) protein in ATM-dependent response to DNA damage, 5
Repression of stress-induced apoptosis by the H4(D10S170) 5
Suppression of ADP-ribosylation reversal triggers cell vulnerability to alkylating agents 4
Ccdc6 knock-in mice develop thyroid hyperplasia associated to an enhanced CREB1 activity 3
Totale 379
Categoria #
all - tutte 1.606
article - articoli 1.388
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 134
Totale 3.128


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2023/202415 0 0 0 0 0 0 0 0 2 0 13 0
2024/2025364 2 5 66 35 196 47 13 0 0 0 0 0
Totale 379